Fierce Pharma July 7, 2022
Weeks after speculation surrounding a potential Merck acquisition of Seagen first surfaced, the two companies are now reportedly nearing a deal that could be the biopharma world’s largest since 2020—unless antitrust regulators intervene.
Merck is in advanced talks to buy Seagen for about $40 billion or more, or above $200 per share, The Wall Street Journal reports, citing people familiar with the matter.
The companies hope to tie the knot on or before Merck’s second-quarter earnings report, which is set for July 28, the newspaper reports.
This whitepaper explores how duplicate discounts from drug discount programs adversely impact drug manufacturer finances, why the expansion of the 340B program has magnified the problem and stakeholder frustrations,...
Today's Sponsors
Today's Sponsor